<span item_type="fundamental" item_id="eb7dc7373c858c772a58755a31de15a3" counter_id="ST/US/DSS" env="prod"></span><span item_type="announcement" item_id="582792623374668545" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 6.392 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.25.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -3.205 M.</p><p></p><h3>Product Packaging</h3><ul><li><strong>Revenue</strong>: $4,935,000 for the three months ended September 30, 2025, compared to $4,846,000 for the same period in 2024. For the nine months ended September 30, 2025, revenue was $13,221,000 compared to $11,466,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Cost of Revenue</strong>: $4,380,000 for the three months ended September 30, 2025, compared to $4,350,000 in 2024. For the nine months ended September 30, 2025, cost was $12,274,000 compared to $10,715,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Commercial Lending</h3><ul><li><strong>Revenue</strong>: $7,000 for the three months ended September 30, 2025, compared to $45,000 in 2024. For the nine months ended September 30, 2025, revenue was $37,000 compared to $192,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Cost of Revenue</strong>: -$192,000 for the three months ended September 30, 2025, compared to $252,000 in 2024. For the nine months ended September 30, 2025, cost was $20,000 compared to $719,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Direct Marketing</h3><ul><li><strong>Revenue</strong>: No revenue reported for the three months ended September 30, 2025, compared to $0 in 2024. For the nine months ended September 30, 2025, revenue was $0 compared to $3,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Cost of Revenue</strong>: No cost reported for the three months ended September 30, 2025, compared to -$2,000 in 2024. For the nine months ended September 30, 2025, cost was -$7,000 compared to -$2,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Biotechnology</h3><ul><li><strong>Revenue</strong>: $11,000 for the three months ended September 30, 2025, compared to $1,000 in 2024. For the nine months ended September 30, 2025, revenue was $32,000 compared to $2,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Cost of Revenue</strong>: $12,000 for the three months ended September 30, 2025, compared to $10,000 in 2024. For the nine months ended September 30, 2025, cost was $36,000 compared to $30,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Securities</h3><ul><li><strong>Revenue</strong>: $1,439,000 for the three months ended September 30, 2025, compared to $707,000 in 2024. For the nine months ended September 30, 2025, revenue was $3,340,000 compared to $2,018,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Cost of Revenue</strong>: $1,868,000 for the three months ended September 30, 2025, compared to $1,993,000 in 2024. For the nine months ended September 30, 2025, cost was $4,430,000 compared to $5,804,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Corporate</h3><ul><li><strong>Operating Expense</strong>: $11,065,000 for the three months ended September 30, 2025, compared to $654,000 in 2024. For the nine months ended September 30, 2025, expense was $12,957,000 compared to $2,164,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Operating Cash Flow</strong>: Net cash used by operating activities was -$7,576,000 for the nine months ended September 30, 2025, compared to -$5,889,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Investing Cash Flow</strong>: Net cash provided by investing activities was $12,080,000 for the nine months ended September 30, 2025, compared to $9,916,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Financing Cash Flow</strong>: Net cash used by financing activities was -$8,816,000 for the nine months ended September 30, 2025, compared to $989,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to continue leveraging its existing business lines, focusing on increasing revenue through new customer orders and expanding existing customer relationships, particularly in the Printed Products and Securities segments.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li><li><strong>Non-Core Business</strong>: The company is evaluating the status of its merger and share exchange agreement with Dr Ashleys Limited, with the closing date uncertain due to pending regulatory approval.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/771999/000149315225023374/form10-q.htm"></span></li></ul>

DSS | 10-Q: FY2025 Q3 Revenue: USD 6.392 M